Novocure Announces the Completion of Enrollment of its PANOVA Trial of Tumor Treating Fields Plus Gemcitabine for Treatment of Pancreatic Cancer

The PANOVA trial will now be expanded to treat an additional twenty advanced pancreatic cancer patients with concomitant TTFields, gemcitabine and nab-paclitaxel ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today that the last patient has been enrolled in the PANOVA trial, an open-label phase II clinical trial of Tumor Treating Fields (TTFields) …

Novocure Announces $100 Million Term Loan Agreement with Pharmakon Advisors

ST. HELIER, Jersey–(BUSINESS WIRE)–Novocure, a commercial stage oncology company, announced today that it has entered into a term loan agreement with an investment fund managed by Pharmakon Advisors LP. The agreement provides Novocure with up to $100 million of available borrowing capacity. Under the terms of the agreement, Pharmakon will provide $25 million at closing. …